Future Opportunities to Leverage the Alzheimer's Disease Neuroimaging Initiative: Workshop Summary (2011)
Chapter: Appendix B: Workshop Agenda
Appendix B
Workshop Agenda
STATE-OF-THE-ART METHODS FOR EXPLORING CENTRAL NERVOUS SYSTEM DEVELOPMENTAL AND NEURODEGENERATIVE DISORDERS: A WORKSHOP
Monday, July 12
2010 International Conference on Alzheimer’s Disease
|
1:00 p.m. |
Session Overview |
|
|
WILLIAM POTTER Cochair Emeritus, Neuroscience Steering Committee, FNIH Biomarkers Consortium Former Vice President, Translational Neuroscience, Merck & Co., Inc. |
|
|
WILLIAM THIES Vice President, Medical & Scientific Relations National Alzheimer’s Association |
|
1:10 p.m. |
Key Elements of ADNI and Moving Forward: What Lessons Can Be Learned for Moving Forward? The National Institutes of Health Perspective |
|
|
NEIL BUCKHOLTZ Chief, Dementias of Aging Branch Division of Neuroscience National Institute on Aging |
|
1:20 p.m. |
Key Elements of Japanese ADNI and Moving Forward: What Lessons Can Be Learned for Moving Forward? |
|
|
IKUHISA SAWADA Project Coordinator, Biotechnology and Medical Technology Development Department New Energy and Industrial Technology Development Organization |
|
1:30 p.m. |
Key Elements of European ADNI and Moving Forward: What Lessons Can Be Learned for Moving Forward? |
|
|
GIOVANNI B. FRISONI Vice Scientific Director, IRCCS Centro San Giovanni di Dio FBF The National Centre for Alzheimer’s and Mental Diseases |
|
1:40 p.m. |
Key Elements of Australian ADNI and Moving Forward: What Lessons Can Be Learned for Moving Forward? |
|
|
CHRISTOPHER ROWE Director, Department of Nuclear Medicine and Centre for PET Professorial Fellow, University of Melbourne–Austin Health |
|
1:50 p.m. |
Key Elements of ADNI and Moving Forward: What Lessons Can Be Learned For Moving Forward? An Industry Perspective |
|
|
HOWARD FELDMAN Vice President and Therapeutic Area Head, Global Clinical Research Neuroscience Bristol-Myers Squibb |
|
2:00 p.m. |
Panel Discussion: Moving Forward—Identifying Opportunities and Future Synergies for ADNI 2 |
|
|
STEVEN PAUL, Panel Chair Executive Vice President, Science (Former) Eli Lilly |
|
|
GIOVANNI B. FRISONI Vice Scientific Director, IRCCS Centro San Giovanni di Dio FBF The National Centre for Alzheimer’s and Mental Diseases |
|
|
HOWARD FELDMAN Vice President and Therapeutic Area Head, Global Clinical Research Neuroscience Bristol-Myers Squibb |
|
|
NEIL BUCKHOLTZ Chief, Dementias of Aging Branch Division of Neuroscience National Institute on Aging |
|
|
WILLIAM POTTER Cochair Emeritus, Neuroscience Steering Committee, FNIH Biomarkers Consortium Former Vice President, Translational Neuroscience, Merck & Co., Inc. |
|
|
CHRISTOPHER ROWE Director, Department of Nuclear Medicine and Centre for PET Professorial Fellow, University of Melbourne–Austin Health |
|
|
IKUHISA SAWADA Project Coordinator, Biotechnology and Medical Technology Development Department New Energy and Industrial Technology Development Organization |
